Last reviewed · How we verify
qNIV Vaccine with Matrix-M Adjuvant
qNIV Vaccine with Matrix-M Adjuvant is a Small molecule drug developed by Novavax. It is currently in Phase 2 development.
At a glance
| Generic name | qNIV Vaccine with Matrix-M Adjuvant |
|---|---|
| Sponsor | Novavax |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine (PHASE1, PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- qNIV Vaccine with Matrix-M Adjuvant CI brief — competitive landscape report
- qNIV Vaccine with Matrix-M Adjuvant updates RSS · CI watch RSS
- Novavax portfolio CI
Frequently asked questions about qNIV Vaccine with Matrix-M Adjuvant
What is qNIV Vaccine with Matrix-M Adjuvant?
qNIV Vaccine with Matrix-M Adjuvant is a Small molecule drug developed by Novavax.
Who makes qNIV Vaccine with Matrix-M Adjuvant?
qNIV Vaccine with Matrix-M Adjuvant is developed by Novavax (see full Novavax pipeline at /company/novavax).
What development phase is qNIV Vaccine with Matrix-M Adjuvant in?
qNIV Vaccine with Matrix-M Adjuvant is in Phase 2.
Related
- Manufacturer: Novavax — full pipeline
- Compare: qNIV Vaccine with Matrix-M Adjuvant vs similar drugs
- Pricing: qNIV Vaccine with Matrix-M Adjuvant cost, discount & access